Neuropilin-1 Expression Is Induced on Tolerant Self-Reactive CD8+ T Cells but Is Dispensable for the Tolerant Phenotype
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neuropilin-1 Expression Is Induced on Tolerant Self-Reactive CD8+ T Cells but Is Dispensable for the Tolerant Phenotype
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 10, Pages e110707
Publisher
Public Library of Science (PLoS)
Online
2014-10-25
DOI
10.1371/journal.pone.0110707
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
- (2014) Amita Patnaik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting CD8+ T-cell tolerance for cancer immunotherapy
- (2014) Stephanie R Jackson et al. Immunotherapy
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Neuropilin 1: function and therapeutic potential in cancer
- (2013) Belal Chaudhary et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients
- (2013) Agnieszka Piechnik et al. INTERNATIONAL JOURNAL OF CANCER
- Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
- (2013) Greg M. Delgoffe et al. NATURE
- Liver-Primed Memory T Cells Generated under Noninflammatory Conditions Provide Anti-infectious Immunity
- (2013) Jan P. Böttcher et al. Cell Reports
- Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance
- (2012) M. M. Berrien-Elliott et al. CANCER RESEARCH
- Neuropilin-1 Identifies a Subset of Bone Marrow Gr1- Monocytes That Can Induce Tumor Vessel Normalization and Inhibit Tumor Growth
- (2012) A. Carrer et al. CANCER RESEARCH
- Neuropilin 1 deficiency on CD4+Foxp3+regulatory T cells impairs mouse melanoma growth
- (2012) Wiebke Hansen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A vascular niche and a VEGF–Nrp1 loop regulate the initiation and stemness of skin tumours
- (2011) Benjamin Beck et al. NATURE
- Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis
- (2011) Benjamin D. Solomon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Neuroimmune Semaphorin-3A Reduces Inflammation and Progression of Experimental Autoimmune Arthritis
- (2010) A. Catalano JOURNAL OF IMMUNOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer
- (2009) Alessandra Battaglia et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- Neuropilin-1 Expression on Regulatory T Cells Enhances Their Interactions with Dendritic Cells during Antigen Recognition
- (2008) Milka Sarris et al. IMMUNITY
- Neuropilin-1 is a receptor for transforming growth factor β-1, activates its latent form, and promotes regulatory T cell activity
- (2008) Yelena Glinka et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer
- (2007) Alessandra Battaglia et al. IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now